Bird Flu Kills over 900 Seals, Sea Lions in South Brazil

File photo: Sea lions are seen on a street of Mar del Plata harbor during the lockdown due to the coronavirus pandemic, in Mar del Plata, some 400 km south of Buenos Aires, Argentina | AFP.
File photo: Sea lions are seen on a street of Mar del Plata harbor during the lockdown due to the coronavirus pandemic, in Mar del Plata, some 400 km south of Buenos Aires, Argentina | AFP.
TT

Bird Flu Kills over 900 Seals, Sea Lions in South Brazil

File photo: Sea lions are seen on a street of Mar del Plata harbor during the lockdown due to the coronavirus pandemic, in Mar del Plata, some 400 km south of Buenos Aires, Argentina | AFP.
File photo: Sea lions are seen on a street of Mar del Plata harbor during the lockdown due to the coronavirus pandemic, in Mar del Plata, some 400 km south of Buenos Aires, Argentina | AFP.

Nearly 1,000 seals and sea lions in southern Brazil have died from bird flu outbreaks, say authorities, who are scrambling to isolate the deadly virus from commercial poultry flocks.
The southernmost state of Rio Grande do Sul has confirmed an unprecedented 942 sea mammal deaths following infection by the highly pathogenic avian influenza (HPAI), which was reported for the first time ever in the South American country this year.
Oceanographer Silvina Botta, at the Rio Grande Federal University (FURG), said the carcasses have to be buried or incinerated as soon as possible to reduce the risk of contaminating humans or other animals.
Scientists have also found some sea mammals convulsing along local beaches, as the virus attacks their nervous system. Under government health regulations, animals have to be euthanized to spare "a very painful death," Botta said.
Since Brazil's first report of HPAI in wild birds in May, the Agriculture Ministry says preventive measures have avoided an outbreak on commercial poultry farms, which could trigger export bans against Brazil, the world's top chicken exporter.
But the virus has run rampant in other animal populations. In addition to the outbreaks among seabirds, seals and sea lions, authorities have collected samples of dead porpoises and penguins found on beaches, with no confirmed results yet.
Botta said the first diagnosis of HPAI-related sea mammal deaths in Rio Grande do Sul came in September, when unusual mortality rates caught scientists' attention. Three towns in the state still have active outbreaks.
She said the contagion among sea mammals appears to have started in Peru and then circled the South American continent, hitting wildlife in Chile, Argentina, Uruguay and now Brazil.
Brazil's Agriculture Ministry reported 148 HPAI outbreaks in the country, mostly along the coast, declaring a health emergency to contain the disease, which it says "is not yet considered endemic in Brazil."
Avian influenza, commonly known as bird flu, has led to the culling of hundreds of millions of farm animals in Europe and the United States.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”